Actovegin vs BPC-157

A side-by-side comparison from PeptideSciences101, the open peptide reference.

Overview

Actovegin is primarily a pain management peptide, while BPC-157 is used for bone & joint.

This page compares Actovegin and BPC-157 across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.

Side-by-side comparison

ActoveginBPC-157
CategoryPain ManagementBone & Joint
Regulatory status (US)Research use onlyCompounding (Rx) — Apr 2026
Typical dosage5-10 ml250-500 mcg
Frequencymultiple weeklydaily
Reported benefitsCirculation-related pain relief, tissue oxygenation, healing supportAccelerated bone healing, cartilage repair, joint support
Reported side effectsRare allergic reactionsMinimal side effects

Key differences

Primary use. Actovegin is categorised under Pain Management, while BPC-157 falls under Bone & Joint. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.

Regulatory status. Actovegin: not FDA-approved; treated as a research compound. BPC-157: not FDA-approved; compounding permitted with a prescription as of April 2026.

Dosing. Actovegin is typically dosed at 5-10 ml (multiple weekly). BPC-157 is typically dosed at 250-500 mcg (daily).

Can you stack them?

Some protocols combine peptides, but stacking Actovegin and BPC-157 has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.

Frequently asked questions

What is the difference between Actovegin and BPC-157?
Actovegin is primarily a pain management peptide, while BPC-157 is used for bone & joint. Actovegin is not FDA-approved; generally classified as a research compound, whereas BPC-157 is not FDA-approved; compounding permitted with a prescription (as of April 2026).
What is Actovegin used for?
Hypoxic pain and healing.
What is BPC-157 used for?
Bone and cartilage healing.
Can you take Actovegin and BPC-157 together?
Some users combine peptides within a single protocol, but stacking Actovegin and BPC-157 has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
Is Actovegin or BPC-157 FDA-approved?
Actovegin is not FDA-approved; generally classified as a research compound. BPC-157 is not FDA-approved; compounding permitted with a prescription (as of April 2026).

Read the full articles

  • Actovegin — full monograph: mechanism, research, dosing & references
  • BPC-157 — full monograph: mechanism, research, dosing & references

More Pain Management comparisons

← All peptide comparisons